Claims for Patent: 5,712,298

Summary for Patent: 5,712,298

Title:	Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Abstract:	Compounds of formula (I), in which one of the substituents R1 or R2 stands for hydrogen, 1-6C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, benzyloxy or totally or partially fluorine-substituted 1-4C-alkoxy, and the other stands for totally or partially fluorine-substituted 1-4C-alkoxy, and R3 stands for phenyl, pyridyl, R31, R32 and R33-substituted phenyl or R34, R35, R36 and R37-substituted pyridyl, in which R31 stands for hydroxy, halogen, cyano, carboxyl, trifluoromethyl 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, amino, mono- or di-1-4C-alkylamino or 1-4C-alkylcarbonylamino; R32 stands for hydrogen, hydroxy, halogen, amino, trifluoromethyl, 1-4C-alkyl or 1-4C-alkoxy; R33 stands for hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy; R34 stands for hydroxy, halogen, cyano, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl or amino; R35 stands for hydrogen, halogen, amino or 1-4C-alkyl; R36 stands for hydrogen or halogen; and R37 stands for hydrogen or halogen. These compounds constitute new effective bronchotherapeutic drugs. ##STR1##
Inventor(s):	Amschler; Hermann (Radolfzell, DE)
Assignee:	BYK Gulden Lomberg Chemische Fabrik GmbH (Konstanz, DE)
Application Number:	08/564,322
Patent Claims:	1. A compound of formula I ##STR2## in which R1 is 1-4C-alkoxy which is completely or partially substituted by fluorine, R2 is 3-5C-cycloalkylmethoxy or benzyloxy, and R3 is 2-bromophenyl, 2,6-dichloro-4-ethoxycarbonylphenyl, 2,6-dimethoxyphenyl, 4-cyano-2-fluorophenyl, 2,4,6-trifluorophenyl, 2-chloro-6-methylphenyl, 2,6-dimethylphenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 3,5-dichloropyrid-4-yl, 3-methylpyrid-2-yl, 2-chloropyrid-3-yl, 3,5-dibromopyrid-2-yl, 2,3,5,6-tetrafluoropyrid-4-yl, 3-chloro-2,5,6-trifluoropyrid-4-yl, 3,5-dichloro-2,6-difluoropyrid-4-yl or 2,6-dichloropyrid-3-yl, a salt thereof, and the N-oxide of a pyridine or a salt thereof. 2. A compound of claim 1, in which R1 is difluoromethoxy, R2 is cyclopropylmethoxy and R3 is 2-bromophenyl, 2,6-dichloro-4-ethoxycarbonylphenyl, 2,6-dimethoxyphenyl, 4-cyano-2-fluorophenyl, 2,4,6-trifluorophenyl, 2-chloro-6-methylphenyl, 2,6-dimethylphenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 3,5-dichloropyrid-4-yl, 3-methylpyrid-2-yl, 2-chloropyrid-3-yl, 3,5-dibromopyrid-2-yl, 2,3,5,6-tetrafluoropyrid-4-yl, 3-chloro-2,5,6-trifluoropyrid-4-yl, 3,5-dichloro-2,6-difluoropyrid-4-yl or 2,6-dichloropyrid-3-yl, a salt thereof, and the N-oxide of a pyridine or a salt thereof. 3. A medicament composition containing an effective amount of a compound according to claim 1 and a suitable carrier therefor. 4. A method which comprises administering an effective amount of a phosphodiesterase (PDE) inhibitor to a subject in need of such therapy and wherein the phosphodiesterase inhibitor is a pharmacologically acceptable compound of claim 1. 5. In a method of compounding a medicament composition comprising a suitable carrier and an effective amount of an active component for treating an airway disorder, the improvement wherein the active component is a compound of claim 1. 6. In a method of compounding a medicament composition having a suitable carrier and an effective amount of a component for treating a dermatosis, the improvement wherein the active component is a compound of claim 1. 7. A compound of claim 2, wherein R3 is 3,5-dichloropyrid-4-yl, a salt thereof, an N-oxide thereof or a salt of an N-oxide thereof. 8. A compound of claim 1 wherein R1 is difluoromethoxy, R2 is cyclobutylmethoxy and R3 is 3,5-dichloropyrid-4-yl, a salt thereof, an N-oxide thereof or a salt of an N-oxide thereof.